Here's How I'd Play the Surging Healthcare Sector
By Costas Bocelli ·
Yesterday, "Big Bill" Spencer showed you one of the quieter -- and more interesting -- shifts taking place in this market. Healthcare is getting healthy.
Right after Bill hit "send" on his article the broader Health Care Select Sector SPDR Fund (XLV) spiked deeper into record territory.

So this trend has legs. While much of Wall Street has been looking elsewhere, money has been quietly moving into this corner of the market.
We promised you that today I'd give you a specific way to play it. So let's get right to it.
The stock is: Biodesix Inc. (BDSX) and it happens to be stronger than 98% of its peers in the Healthcare sector.

It's a tiny Healthcare company most investors have probably never heard of. Its market capitalization is only around $235 million. But don't confuse small with weak.
Because according to our Urgency algorithm, BDSX is currently stronger than 98% of its peers.
Better still, the stock is hitting fresh 52-week highs. And before we're finished, I'm going to show you why I believe BDSX has a reasonable shot at reaching $40 for a roughly 60% return above its current price.
But first, let's remind ourselves how we found it.
Follow the Money
Yesterday, we looked at the remarkable improvement taking place inside Healthcare. Our Healthcare sub-sector has climbed from #38 on June 16 to #18. Drugs has been even stronger, rocketing from #25 on June 9 all the way to #8.
And Biomedics Genetics climbed from #34 on June 15 to #15 on July 10 before cooling off and slipping back to #25.
So while every sub-group of the broad Healthcare isn't moving in lockstep, the larger trend has been hard to miss.
And that brings us back to one of the simplest ideas we teach at True Market Insiders: Relative Strength tells us WHAT to own. Breadth (aka Demand) tells us WHEN to own it.
We don't start by searching through thousands of stocks hoping to stumble onto a winner. We look first for the areas attracting money. The sectors being bought with the highest urgency by the biggest institutions. And then we hunt for the strongest stocks inside those groups.
Which brings us back to BDSX...
A Small Company With a Big Niche
Biodesix is a data-driven diagnostic solutions company focused heavily on lung disease and lung cancer. Among other things, it offers blood-based tests that can help doctors evaluate suspicious lung nodules and make treatment decisions for patients diagnosed with lung cancer.
The company also provides diagnostic research, clinical research, development and testing services to biopharmaceutical companies.
This is not a giant, mature Healthcare company. It's a small-cap growth story. And it's growing.
Biodesix recently reported second-quarter revenue of $26.9 million growth of +34% from a year earlier.
- Its core Diagnostic Testing revenue increased 42%.
- Testing volume jumped 38%.
- And gross margins reached 82%.
The company is still losing money, which is important to understand. But those losses have been moving in the right direction: its quarterly net loss improved 37%, while its adjusted EBITDA loss improved 56%.
Encouraging for sure. But none of those numbers, by themselves, are why I'm showing you BDSX today.
The stock itself is telling us something. And this is where things get especially interesting.
Wall Street Is Already Voting
As I write this, BDSX is trading at $25.54. Today alone, the stock is up 14.32%. It traded as high as $26.40 intraday.
And that surge is pushing BDSX into fresh 52-week-high territory. In other words, this stock isn't lying on the floor waiting for somebody to discover it.
As mentioned, BDSX is now stronger than 98% of its peers. That's an important distinction. We're not buying BDSX simply because it's a beaten-down little Healthcare stock and hoping someday everybody else figures out how wonderful it is.
The market has already begun confirming the story. And today's 14% surge is another powerful piece of evidence.
Now, some investors will look at a stock making fresh highs and instinctively think, "Did I miss it?" But that's the wrong question. We're not trying to buy stocks simply because they're cheap.
We're trying to identify strength while there's still lots of room between today's price and the stock's next logical destination. And in the case of BDSX that next destination could be considerably higher.
Which brings us to this look at the price chart.

A Fibonacci Extension study (not shown) on BDSX shows a minimum price objective of $40.38. Call it $40.
But here's what really caught my attention is the blue dotted line. It marks the area around $40.
Look back at 2023 and 2024. BDSX interacted with that general price area again and again, testing it... failing to hold above it... returning to it...
In other words, $40 has mattered to this stock for a long time. And now my Fibonacci Extension is independently pointing us toward almost exactly the same place. That's what technicians call confluence.
Two different pieces of technical evidence pointing toward essentially the same destination.
A minimum price objective $40 from today's price gives a +57% upside. Call it roughly 60%.
If this advance continues, $40 is a logical area for BDSX to gravitate toward. That's a pretty compelling potential destination for a stock that's already demonstrating this much strength.
There's one other detail I think is worth knowing.
Another Vote of Confidence in BDSX
Earlier this month, Biodesix director and major shareholder Jack Schuler bought another 15,000 shares of BDSX at prices around $24 to $24.50. That's roughly a $367,000 purchase. And it's awfully close to where BDSX is trading today.
Now, insider buying doesn't guarantee anything, because nothing does.
And because BDSX is a small-cap stock that isn't yet profitable, I'd expect considerably more volatility here than I'd expect from a giant Healthcare company like Johnson & Johnson.
But investing is about putting probabilities in your favor. And look at the evidence we've assembled. Healthcare is strengthening. BDSX is stronger than 98% of its peers. The company is growing revenue rapidly. The stock is hitting fresh 52-week highs (surging another 14% today).
An insider has recently been buying shares. And two completely different pieces of technical evidence point toward roughly $40. That's a setup worth paying attention to.
There's also a larger lesson here. Yesterday, Bill reminded you what happened with Software. It went from dead last in our rankings all the way to #4.
Then we talked about Precious Metals. When Chris Rowe became extremely bullish on that beaten-down sector back on July 13, it ranked: #45 out of 45.
Today? Take a look!

Precious Metals subsequently rocketed all the way to the top spot of our Urgency rankings.
And yesterday afternoon, Chris showed us another beaten-down part of the market that has his attention now.
That's the recurring pattern. Markets change their minds. Money moves. And yesterday's losers start showing strength.
And eventually, if the move becomes powerful enough, everybody notices.
Our job is to notice first. That's what our sector work is designed to help us do.
Yesterday afternoon, Chris opened our normally members-only Sector Focus Q&A to all True Market Insiders readers.
And if you weren't able to join us live, we've posted the replay. In it, Chris shows you what he's seeing in another beaten-down area of the market right now.
He also demonstrates how he can potentially pull additional cash out of a great stock without selling his shares (what we call collecting a “Super Dividend”).
But whether you watch the replay or not, I hope you'll take one idea away from these past two days. Don't just ask what's strong. Ask, "what's getting stronger?" Then look for the strongest stocks benefiting from that change.
Right now, Healthcare is getting stronger. And Biodesix Inc. (BDSX) is one of the stocks telling us investors have already begun to notice.
Thanks for reading,
Costas
